Presence of diffuse leptomeningeal disease or gliomatosis cerebri.

Systemic corticosteroid therapy \> 2 mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment.

Patients who have undergone stereotactic radiosurgery prior to or following surgical resection, or the placement of Gliadel® Wafers.

Known allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme